225 related articles for article (PubMed ID: 36362392)
21. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2013 Jul; 140(2):233-40. PubMed ID: 23860926
[TBL] [Abstract][Full Text] [Related]
22. Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income.
Ursem CJ; Bosworth HB; Shelby RA; Hwang W; Anderson RT; Kimmick GG
J Womens Health (Larchmt); 2015 May; 24(5):403-8. PubMed ID: 25884292
[TBL] [Abstract][Full Text] [Related]
23. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
24. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
25. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
26. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
27. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
28. Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?
Walsh EM; Nunes R; Wilkinson MJ; Santa-Maria CA
Curr Oncol Rep; 2020 Oct; 22(12):123. PubMed ID: 33015752
[TBL] [Abstract][Full Text] [Related]
29. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Yamashita H; Yando Y; Nishio M; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Breast Cancer; 2006; 13(1):74-83. PubMed ID: 16518065
[TBL] [Abstract][Full Text] [Related]
31. Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?
Cucciniello L; Gerratana L; Del Mastro L; Puglisi F
Cancer Treat Rev; 2022 Nov; 110():102445. PubMed ID: 35944419
[TBL] [Abstract][Full Text] [Related]
32. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
33. Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.
Vaz-Luis I; Francis PA; Di Meglio A; Stearns V
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-15. PubMed ID: 33989019
[TBL] [Abstract][Full Text] [Related]
34. Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer.
Hilal T; Mi L; Ertz-Archambault NM; Almquist DR; Anderson KS; Gray RJ; Pockaj BA; Northfelt DW
Breast J; 2020 Jul; 26(7):1449-1451. PubMed ID: 31876083
[No Abstract] [Full Text] [Related]
35. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
36. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
39. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
Richman J; Dowsett M
Nat Rev Clin Oncol; 2019 May; 16(5):296-311. PubMed ID: 30563978
[TBL] [Abstract][Full Text] [Related]
40. Extended adjuvant endocrine therapy - A standard to all or some?
Ribnikar D; Sousa B; Cufer T; Cardoso F
Breast; 2017 Apr; 32():112-118. PubMed ID: 28152498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]